2Suppliers
0Customers
3Debt Items
0Related Chains

Brainstorm Cell Therapeutics Inc. Suppliers

TickerNameConfidenceEvidence
RAMOT RAMOT 90% Under this agreement, our Israeli subsidiary pays royalties to Ramot ranging between three percent (3%) and five percent (5%) of all net sales derived from the licensed intellectual property
SUPPLIER SUPPLIER 90% During the reporting period, the Company settled outstanding accounts payable to a supplier in the amount of $ 450 through the issuance of 281,250 shares of common stock.

Brainstorm Cell Therapeutics Inc. Customers

No clients on recordNo downstream customers found in our database for Brainstorm Cell Therapeutics Inc..

Brainstorm Cell Therapeutics Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
BCLI-DEBT Debt stack $1.2M 90% Market cache reports total debt of $1.2M.
BCLI-DEBT-8102 Warrants outstanding: 250000 90% xbrl warrant detail from xbrl 2025-12-31.
BCLI-DEBT-8103 Xbrl Convertible 90% xbrl convertible detail from xbrl 2013-12-31.

Brainstorm Cell Therapeutics Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Brainstorm Cell Therapeutics Inc..

Brainstorm Cell Therapeutics Inc. Ownership

HolderNameConfidenceEvidence
BCLI-OWNER-OSAIC-HOLDINGS-INC OSAIC HOLDINGS, INC. 90% 13F overlay lists OSAIC HOLDINGS, INC. as top holder; 5 tracked holders.

Brainstorm Cell Therapeutics Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.